Clinicopathological characteristics of 31 pediatric patients with B-cell mPTLD
| . | PTLD-DLBCL, n = 24 . | PTLD-BL, n = 7 . | Total, n = 31 . |
|---|---|---|---|
| Mean age (range, years old) | 8 (2-17) | 12 (6-16) | 9 (2-17) |
| Male | 13/24 (54%) | 5/7 (71%) | 18/31 (58%) |
| Female | 11/24 (46%) | 2/7 (29%) | 13/31 (42%) |
| Localization | |||
| Extranodal involvement | 17/23 (74%) | 6/7 (86%) | 23/30 (77%) |
| Gastrointestinal tract | 17/23 (74%) | 4/6 (67%) | 21/29 (72%) |
| Stage | |||
| Stage I | 1/19 (5%) | 1/7 (14%) | 2/26 (8%) |
| Stage II | 3/19 (16%) | 0/7 (0%) | 3/26 (11%) |
| Stage III | 14/19 (74%) | 2/7 (29%) | 16/26 (62%) |
| Stage IV | 1/19 (5%) | 4/7 (57%) | 5/26 (19%) |
| COO (NanoString and/or Hans algorithm)∗ | |||
| GCB | 2/22 (9%) | 7/7 (100%) | 9/29 (31%) |
| ABC/non-GCB | 20/22 (91%) | 0/7 (0%) | 20/29 (69%) |
| EBER hybridization positive | 21/23 (91%) | 7/7 (100%) | 28/30 (93%) |
| EBV replication | 6/11 (55%) | 0/5 (0%) | 6/16 (38%) |
| Latency pattern | |||
| Latency I | 2/20 (10%) | 6/6 (100%) | 8/26 (31%) |
| Latency II | 6/20 (30%) | 0/6 (0%) | 6/26 (23%) |
| Latency III† | 12/20 (60%) | 0/6 (0%) | 12/26 (46%) |
| Mean time from the transplantation to PTLD diagnosis (range, months) | 24 (2-141) | 74.4 (32-170) | 35 (2-170) |
| Early-onset PTLD | 15/24 (63%) | 0/7 (0%) | 15/31 (48%) |
| Alive with no evidence of disease | 17/24 (71%) | 7/7 (100%) | 24/31 (77%) |
| Died of disease | 5/24 (21%) | 0/7 (0%) | 5/31 (16%) |
| Fulminant PTLD | 3/5 (60%) | 0/0 (0%) | 3/5 (60%) |
| Follow-up (median) (range) | 1.3 y (10 d-14.1 y) | 5.2 y (2.1-22.6 y) | 2.7 y (10 d-22.6 y) |
| 5y-DFS | 78.9% | 100% | 83.7% |
| . | PTLD-DLBCL, n = 24 . | PTLD-BL, n = 7 . | Total, n = 31 . |
|---|---|---|---|
| Mean age (range, years old) | 8 (2-17) | 12 (6-16) | 9 (2-17) |
| Male | 13/24 (54%) | 5/7 (71%) | 18/31 (58%) |
| Female | 11/24 (46%) | 2/7 (29%) | 13/31 (42%) |
| Localization | |||
| Extranodal involvement | 17/23 (74%) | 6/7 (86%) | 23/30 (77%) |
| Gastrointestinal tract | 17/23 (74%) | 4/6 (67%) | 21/29 (72%) |
| Stage | |||
| Stage I | 1/19 (5%) | 1/7 (14%) | 2/26 (8%) |
| Stage II | 3/19 (16%) | 0/7 (0%) | 3/26 (11%) |
| Stage III | 14/19 (74%) | 2/7 (29%) | 16/26 (62%) |
| Stage IV | 1/19 (5%) | 4/7 (57%) | 5/26 (19%) |
| COO (NanoString and/or Hans algorithm)∗ | |||
| GCB | 2/22 (9%) | 7/7 (100%) | 9/29 (31%) |
| ABC/non-GCB | 20/22 (91%) | 0/7 (0%) | 20/29 (69%) |
| EBER hybridization positive | 21/23 (91%) | 7/7 (100%) | 28/30 (93%) |
| EBV replication | 6/11 (55%) | 0/5 (0%) | 6/16 (38%) |
| Latency pattern | |||
| Latency I | 2/20 (10%) | 6/6 (100%) | 8/26 (31%) |
| Latency II | 6/20 (30%) | 0/6 (0%) | 6/26 (23%) |
| Latency III† | 12/20 (60%) | 0/6 (0%) | 12/26 (46%) |
| Mean time from the transplantation to PTLD diagnosis (range, months) | 24 (2-141) | 74.4 (32-170) | 35 (2-170) |
| Early-onset PTLD | 15/24 (63%) | 0/7 (0%) | 15/31 (48%) |
| Alive with no evidence of disease | 17/24 (71%) | 7/7 (100%) | 24/31 (77%) |
| Died of disease | 5/24 (21%) | 0/7 (0%) | 5/31 (16%) |
| Fulminant PTLD | 3/5 (60%) | 0/0 (0%) | 3/5 (60%) |
| Follow-up (median) (range) | 1.3 y (10 d-14.1 y) | 5.2 y (2.1-22.6 y) | 2.7 y (10 d-22.6 y) |
| 5y-DFS | 78.9% | 100% | 83.7% |